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Abstract Rapl (Krev-1) is a small GTPase first identified as a 
transformation suppressor of K-ras. This GTPase is very similar 
to Ras, particularly in the effector region, but its function is still 
elusive. Recent progress in the search for Rapl function has come 
from the development of a novel assay to measure Rapl 
activation. Using this assay activation of Rapl was observed in 
human platelets and neutrophils after stimulation with various 
agonists. We speculate that Rapl plays a role in one of the 
specialised functions of these cells. 
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1. Introduction 
To identify proteins involved in oncogenic Ras transforma-
tion, Noda and coworkers introduced cDNA libraries into v-
K-ras-transformed fibroblasts and selected for flat-revertants 
of the transformed phenotype. One of the clones obtained 
(Krev-1) encoded a protein which showed great homology 
with the small GTPase Ras [1]. In particular, the similarity 
with the effector domain of Ras was striking (Fig. 1). At the 
same time low stringency hybridisation of various cDNA li-
braries with Ras cDNA revealed the same protein, which is 
now commonly called Rapl [2,3]. Rapl consists of two iso-
forms, Rapla and Raplb, which differ mainly at the C-termi-
nus. Since most experimental approaches did not discriminate 
between the two we will refer to both as Rapl. Characteristic 
features of Rapl are its geranylgeranyl modification at the C-
terminus, which is responsible for membrane attachment, and 
a threonine residue at position 61. In most other GTPases this 
residue is a glutamine. Substitution of threonine for glutamine 
in Ras resulted in a weakly oncogenic activation. Indeed, 
Rapl has a 10-fold lower intrinsic GTPase activity than 
Ras, but is still sensitive to RapGTPase activating proteins 
(RapGAPs) (for review see [4]). 
The striking similarity of the effector domains of Ras and 
Rapl suggested that Rapl may bind to the same effectors as 
Ras. For Ras several effectors have been identified, most no-
tably (i) the serine-threonine kinase Rafl, (ii) phosphatidyl-
inositol 3-kinase and (iii) Ral guanine nucleotide exchange 
factors (RalGEFs). For both Rafl and RalGEF it has been 
shown that they indeed interact with active Rapl. Importantly 
this interaction does not seem to lead to activation of the 
effectors, providing a simple model for the antagonistic effect 
of Rapl on Ras signalling [5,6]. 
The hypothesis that Rapl functions in a pathway which is 
antagonistic to Ras signalling was further developed by re-
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ports that cAMP can both interfere in Ras signalling at the 
level of Rafl [7] and phosphorylate [8] or activate Rapl [9]. 
However, little evidence exists that indeed cAMP-mediated 
inhibition of Rafl is mediated by Rapl activation. Further-
more, we should be aware that thus far little solid evidence 
exists that any antagonistic effect on Ras signalling is medi-
ated by Rapl, questioning the physiological relevance of this 
effect. 
2. Rapl expression and localisation 
Recent results in specialised cell types indicate that Rapl 
has additional functions apart from being an antagonist of 
Ras signalling. A first clue for a specialised function of 
Rapl came from expression and localisation studies. 
Although Rapl is ubiquitously expressed, it is particularly 
abundant in human platelets [10]. Platelets are anuclear cell 
fragments that adhere to sites of injury in a blood vessel and 
aggregate to form a blood clot. To perform this function 
platelets are activated by a variety of platelet agonists, of 
which thrombin is the most potent. During activation three 
main processes are induced: (i) secretion of a variety of com-
ponents, including ADP and fibrinogen (ii) cytoskeletal rear-
rangements and (iii) adhesion and aggregation by integrin 
activation (predominantly ocIIbp3). In platelets Rapl is 
mainly localised in the plasma membrane or in the membrane 
of the open canalicular system. Some localisation is observed 
in the membranes of oc-granules [11]. 
Rapl is also abundant in neutrophils. Neutrophils are 
phagocytic cells that are induced to migrate into the extravas-
cular tissue by, for instance, chemoattractants produced by 
bacteria. In these cells Rapl is also located mainly in the 
plasma membrane and in specific granules [12,13]. 
Interestingly, both in platelets and neutrophils Rapl trans-
locates from the granules to the plasma membrane after sim-
ulation, but whether this indicates a function of Rapl in se-
cretion or whether this is the consequence of secretion is 
unclear. In contrast, in fibroblasts Rapl is mainly localised 
in either the mid-Golgi compartment or the early and late 
endosomes [14,15]. 
3. Rapl activation 
Until recently little information was available on the signal-
ling pathways in which Rapl may be involved. This was due 
to the absence of suitable antisera to precipitate Rapl to 
measure activation, i.e. an increase in the GTP-bound state 
after stimulation. However, a novel type of assay to identify 
active GTPases was recently developed. This assay makes use 
of activation-specific probes, which only recognise the GTP-
bound form of a particular GTPase. For Rapl the activation-
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Fig. 1. Comparison of the effector domains of Ras and Rapl. Indicated are the regions between residues 16 and 55. The core effector domain 
of Ras spans the residues 32-40. Mutations in this region affect signalling from active Ras, without affecting guanine nucleotide binding. The 
asterisk indicates a difference between RaplA and RaplB. The other differences are at the C-terminus. 
specific probe is the Rap binding domain (RBD) of RalGDS 
[16]. This 97 amino acid domain binds to the GTP-bound 
form of Rapl with an in vitro affinity of 10 nM, whereas 
the affinity for RapGDP is three orders of magnitude lower 
[16,17]. 
In platelets Rapl is activated by thrombin and by most if 
not all other platelet agonists. After thrombin stimulation 
more than 50% of Rapl is activated within 30 s [16]. In com-
bination with the abundant expression of Rapl this indicates 
that a massive activation of Rapl occurs. Also after stimula-
tion of neutrophils with the chemoattractant fMLP, Rapl is 
activated, but less pronouncedly so than after platelet stimu-
lation (M'Rabet, Coffer, Zwartkruis, Franke, Koenderman 
and Bos, manuscript in preparation). In contrast, in the A14 
fibroblast cell line we did not observe any increase in Rapl 
activation after stimulation with thrombin, LPA, or peptide 
growth factors, such as EGF, PDGF, or insulin. However, in 
A14 cells the basal level of the GTP-bound form was clearly 
higher than in platelets or neutrophils (van Triest, Franke, 
Zwartkruis and Bos, unpublished observation). It could well 
be that in fibroblasts Rapl is involved in a 'housekeeping' 
process, whereas in platelets and neutrophils Rapl is involved 
in specialised processes. Surprisingly, cAMP also did not re-
sult in any increase in Rapl activation in NIH-3T3 cells and 
Ratl fibroblasts (van Triest, Franke, Zwartkruis and Bos, 
unpublished observation). This result is in apparent contrast 
to the finding of Altschuler et al. [9] showing activation of 
ectopically expressed epitope-tagged Rapl in Ras-transformed 
fibroblasts by cAMP. Perhaps the Rapl activation system in 
fibroblasts can be induced by oncogenic Ras. 
4. Rapl in platelets 
In human platelets, thrombin-induced Rapl activation is 
mediated by the activation of phospholipase C and the in-
crease in intracellular calcium concentration (Fig. 2). This 
activation occurs prior to and is independent of secretion, 
cytoskeletal rearrangements and integrin activation [16]. By 
which mechanism calcium activates Rapl, however, is un-
clear. It could be by activation of a GEF, or by inactivation 
of a GAP. The only known specific RapGEF is C3G, a Crk 
SH3 domain-binding guanine nucleotide-releasing factor, but 
information on its involvement in calcium-induced activation 
of Rapl in platelets awaits further experiments [18]. Several 
RaplGAPs have been identified, i.e. a p88RaplGAP [19], the 
inositol 2,3,4,5 P4 receptor Gap IP4 [20], tuberin [21] and Spal 
[22]. But their function in the control of Rapl activity is also 
largely elusive. 
After stimulation with thrombin, Rapl is active for at least 
10 min. However, for this sustained activation calcium may 
not be necessary, since the elevated level of calcium declines 
rapidly. Surprisingly, in Glanzmann patients, who lack func-
tional ocIIb|33 integrins, Rapl is rapidly downregulated, fol-
lowing the decline of calcium. This intriguing observation 
suggests that functional integrins are necessary for sustained 
activation, and may point to a positive feedback loop in the 
activation of Rapl (Franke, van Triest, van Willigen, Akker-
man and Bos, manuscript in preparation). 
Rapl activation is inhibited by the platelet antagonist PGI2 
[16]. PGI2 inhibits platelet function by increasing the levels of 
cAMP and the subsequent activation of protein kinase A. 
Previously it was shown that Rapl is a substrate for protein 
kinase A and indeed after PGI2 treatment of platelets, Rapl is 
phosphorylated stoichiometrically [8,16]. However, this phos-
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Fig. 2. A simplified model of Rapl activation in human platelets. 
For explanation see text. 
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phorylation occurs much later than Rapl inactivation and 
phosphorylation of Rapl per se did not inhibit thrombin-in-
duced activation of Rapl [16]. These results indicated that 
phosphorylation of Rapl by PKA is not responsible for its 
inactivation. Phosphorylation of Rapl has been implicated in 
the translocation of Rapl to the cytoplasm, but details of this 
process are lacking [23]. Alternatively, activation of Rapl-
GAP may be responsible for the inhibition of Rapl, since 
this protein is also phosphorylated by protein kinase A [24]. 
After thrombin stimulation Rapl also associates with the 
cytoskeleton [25]. This association does not interfere in the 
activation of Rapl, as shown by inhibition studies with cyto-
chalasin D, an inhibitor of actin polymerisation. This inhib-
itor prevents cytoskeletal association of Rapl but not activa-
tion [16]. Perhaps cytoskeletal association of Rapl reflects a 
downstream event induced by Rapl activation. However, sev-
eral other agonists that result in Rapl activation and platelet 
activation, such as ADP and thromboxane A2, do not lead to 
this strong cytoskeletal association. 
5. Rapl in neutrophils 
A clue for the function of Rapl in neutrophils was obtained 
by the finding that Rapl associates with flavocytochrome b, a 
component of the NADPH-oxidase system [26]. Although in 
vitro Rapl is not necessary for the assembly and the function-
ing of the oxidase system, in vivo both a dominant negative 
mutant of Rapl and a constitutively active mutant of Rapl 
inhibited oxidative burst in differentiated HL60 cells and in a 
EBV-transformed B-cell line [27,28]. These results were inter-
preted that cycling of Rapl between the GDP- and GTP-
bound states is necessary for regulated oxidative burst. Com-
patible with a role of Rapl in the regulation of the oxidative 
burst is our observation that Rapl is rapidly activated by the 
chemoattractant fMLP, a strong inducer of oxidative burst in 
primed neutrophils. However, a similar fMLP-induced activa-
tion of Rapl is observed in unprimed neutrophils, where 
fMLP is unable to induce oxidative burst (M'Rabet, Coffer, 
Zwartkruis, Franke, Koenderman and Bos, manuscript in 
preparation). This indicates that Rapl activation alone is 
probably not sufficient to induce burst. 
6. Downstream targets of Rapl 
In principle all proteins that interact with the GTP-bound 
form of Rapl and not with the GDP-bound form are putative 
effector proteins of Rapl. As mentioned above, RaplG T P does 
interact with Ras effector molecules, but for Rafl and for 
RalGEFs these complexes seem to be inactive. Association 
of Rapl G T P with RafB, a close relative of Rafl [18], and 
with protein kinase C [29] leads to activation of these kinases 
in vitro. Whether this activation also occurs in vivo awaits 
further experiments. Other putative effector molecules are 
the already mentioned RaplGAPs, since they also specifically 
bind to the GTP-bound form of Rapl. Unfortunately, for 
none of these putative effector molecules it is clear whether 
they mediate Rapl function. 
7. A specific function of Rapl 
Although the function of Rapl in platelets and in neutro-
phils is still elusive, it is tempting to speculate that Rapl plays 
an important role in one of the specialised functions of these 
cells. Interestingly, in the budding yeast Saccharomyces cere-
visiae, the Rapl homologue RSR1 (BUD1) plays a role in the 
selection of the bud site. In addition, RSR1 interacts with 
CDC24, a GEF for the small GTPase CDC42, which in yeast 
is involved in bud site assembly and in mammalian cells in the 
formation of actin-rich cell surface protrusions (filopodia) 
[30]. All these processes are highly localised. Perhaps Rapl 
serves a similar function in mammalian cells, i.e. the selection 
of sites where protein complexes have to be formed. In plate-
lets these complexes could be focal adhesion type of com-
plexes responsible for cell adhesion, or fusion sites for regu-
lated secretion [16]. In neutrophils it could be the formation of 
phagosomes, responsible for oxidative burst [31]. A common 
denominator in these events is the proper connection of the 
various complexes to the cytoskeleton and perhaps Rapl is 
involved in this process. Maybe Rapl mediates signals that 
induce the formation of these complexes and executes this 
specialised function by using similar effectors as Ras but in 
a specialised cellular environment. Alternatively, Rapl may be 
directly involved in the assembly of the complexes, for in-
stance by association with components of a complex such as 
flavocytochrome b of the NADPH oxidase complex [26]. 
With the development of activation-specific probes to iden-
tify signals that activate Rapl and the availability of specific 
dominant negative mutants, the secrets of Rapl will be un-
ravelled rapidly. 
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